Physician profile
Beena Syed
NPI 1275840480
$5,995.98
in general payments reported to CMS, 2019-2025
36 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $754 · 2021: $940 · 2022: $1,155 · 2023: $1,221 · 2024: $686 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $976.49 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $871.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $557.57 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $466.01 | 2019-2025 | |
| Amgen INC. | $419.44 | 2020-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $267.33 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $229.86 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $229.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.16 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $184.82 | 2020-2021 | |
| Astellas Pharma US INC | $164.95 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $158.64 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $148.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $139.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.30 | 2019-2025 | Xifaxan, Trulance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $134.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $106.38 | 2019-2023 | Spravato |
| Lilly USA, LLC | $103.28 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Amarin Pharma, INC. | $72.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $52.15 | 2019-2021 | |
| Exact Sciences Corporation | $45.61 | 2023-2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $44.86 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $39.24 | 2024-2025 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $39.17 | 2019-2021 | |
| Kyowa Kirin, INC. | $30.44 | 2020 | |
| Esperion Therapeutics, INC. | $28.66 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.21 | 2021 | |
| Corium, LLC | $20.10 | 2022 | |
| Dexcom, INC. | $20.05 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $19.81 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $16.96 | 2025 | Symbravo |
| Boston Scientific Corporation | $14.88 | 2023 | Watchman Access System |
| Alfasigma USA, INC. | $13.32 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2021 | |
| Sanofi Pasteur INC. | $11.38 | 2020 | |
| Cashflow Solutions, LLC | $8.70 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beena Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.